Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

References

• De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the ‘common’ neurologic disorders. Neurology 2007;68:326-37
   PubMed Web of Science ®Google Scholar
• De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:10-15
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 1999;52:1214-20
   PubMed Web of Science ®Google Scholar
• Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72:432-8
   PubMed Web of Science ®Google Scholar
• Perez F, Helmer C, Dartigues JF. A 15-year population-based cohort study of the incidence of Parkinson’s disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry 2010;81:742-6
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. PRIAMO study group. The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;11:1641-9
   Google Scholar
• Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol 2008;64(Suppl. 2):565-80
   Google Scholar
• Zahodne LB, Fernandez HH. Parkinson’s psychosis. Curr Treat Options Neurol 2010;12:200-11
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004;19:997-1005
   PubMed Web of Science ®Google Scholar
• Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8
   PubMed Web of Science ®Google Scholar
• Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62(Suppl. 1):S47-S55
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord 2007;13(Suppl. 1):S13-17
   PubMedGoogle Scholar
• Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Parkinsonism Relat Disord 2009;15(Suppl. 1):S9-15
   PubMedGoogle Scholar
• Hauser RA, McDermott MP, Messing S; Parkinson Study Group. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-60
   PubMed Web of Science ®Google Scholar
• Chase TN. The significance of continuing dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998;55(Suppl. 1):1-9
   PubMed Web of Science ®Google Scholar
• Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 2009;9:859-67
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, et al. The ‘on–off’ phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8
   PubMed Web of Science ®Google Scholar
• Tolosa E, Martí MJ, Valldeoriola F, et al. History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology 1998;50(Suppl. 6):S2-10; discussion S44-8
   PubMed Web of Science ®Google Scholar
• Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. Neuropsychiatr Dis Treat 2007;3:335-48
   PubMedGoogle Scholar
• Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalaline after inhibition of peripheral decarboxylase. Nature 1967;215:852-3
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Mentasti M. Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes) [in German]. Arch Psychiatr Nerveknr 1967;210:29-35
   PubMedGoogle Scholar
• Tissot R, Bartholini G, Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol 1969;20:187-90
   PubMed Web of Science ®Google Scholar
• Barbeau A. L-dopa therapy in Parkinson’s disease: a critical review of 9 years’ experience. Can Med Assoc J 1969;101:59-68
   PubMed Web of Science ®Google Scholar
• Block G, Liss C, Reines S, et al. Comparison of immediate release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-7
   PubMed Web of Science ®Google Scholar
• Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-55
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Brunt ER, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;3452:1484-91
   Google Scholar
• Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-17
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DL, Korczyn AD, et al. 056 Study Group. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-50
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(Suppl. 4):S1-136
   PubMedGoogle Scholar
• Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010;25:858-66
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother 2009;10:677-91
   PubMed Web of Science ®Google Scholar
• Colpaert FC, Van Bever WF, Leysen JE. Apomorphine: chemistry, pharmacology, biochemistry. Int Rev Neurobiol 1976;19:225-68
   PubMedGoogle Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004;23(6 Suppl. 4):S8-11
   Google Scholar
• Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease. Parkinson Relat Disord 2009;155:S97-100
   Google Scholar
• Clarke CE, Worth P, Grosset D, et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinson Relat Disord 2009;15:728-41
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Lees AJ, Stern GM. On–off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 1984;107:487-506
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother 2006;6:1403-11
   PubMedGoogle Scholar
• Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause ‘random’ fluctuations of parkinsonian mobility. Neurology 1988;38:419-21
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Nirenberg JM. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63
   PubMed Web of Science ®Google Scholar
• European Parkinson’s Disease Association. Duodopa® Intestinal Gel (levodopa + carbidopa). Parkinson’s Decision Aid. Available at: http://epda.eu.com/medinfo/duodopa/ [Last accessed 18 August 2010]
   Google Scholar
• Papathanou M, van der Laan R, Jenner P, et al. Pulsatile and continuous infusion of L-dopa induce abnormal involuntary movements in 6-OHDA-lesioned rats. Poster presented at The Movement Disorder Society’s 14th Annual Congress of Parkinson’s Disease and Movement Disorders; June 13–17, 2010, Buenos Aires, Argentina
   Google Scholar
• Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol 1993;45:117-22
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-10
   PubMed Web of Science ®Google Scholar
• Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 2009;24:993-1000
   PubMed Web of Science ®Google Scholar
• DANMODIS, Danish Movement Disorder Society; SWEMODIS, Swedish Movement Disorder Society. Duodopa: Scandinavian Consensus I. Treatment with levodopa/carbidopa gel (Duodopa®) in patients with Parkinson’s disease, 2008. Available at: http://info.parkinsonforbundet.se/wp-content/uploads/duodopakonsensus-20081.pdf [Last accessed 18 August 2010]
   Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin Pharmacother 2007;8:657-64
   PubMed Web of Science ®Google Scholar
• Sage JL, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-9
   PubMed Web of Science ®Google Scholar
• Sage JL, Schuh L, Heikkila RE, et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson’s disease. Clin Neuropharmacol 1988;11:36-44
   PubMed Web of Science ®Google Scholar
• Sage JL, Trooskin S, Sonsalla PK, et al. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson’s disease Neurology. 1989;39(11 Suppl. 2):60-3; discussion 72-3
   Google Scholar
• Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa–carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998;97:175-83
   PubMed Web of Science ®Google Scholar
• Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on–off’ fluctuations. Neurology 1993;43:1698-703
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23
   PubMed Web of Science ®Google Scholar
• Nyholm D, Constantinescu R, Holmberg B, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations. Acta Neurol Scand 2009;119:345-8
   PubMed Web of Science ®Google Scholar
• Isacson D, Bingefors K, Kristiansen IS, et al. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118:379-86
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol Scand 2001;104:343-8
   PubMed Web of Science ®Google Scholar
• Nyholm D, Jansson R, Willows T, et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65:1506-7
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis 2008;5:244-6
   PubMed Web of Science ®Google Scholar
• Annic A, Devos D, Seguy D, et al. Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: efficacy and safety [in French]. Rev Neurol (Paris) 2009;165:718-27
   PubMed Web of Science ®Google Scholar
• Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experience with continuous duodenal levodopa–carbidopa infusion (Duodopa): report of six patients. Neurol Sci 2009;30:85-6
   PubMed Web of Science ®Google Scholar
• Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21
   PubMed Web of Science ®Google Scholar
• Pålhagen SE, Dizdar N, Hauge TB, et al. Long-term study on clinical benefits and quality-of-life of intraduodenal levodopa in routine care for a cohort of treatment-naïve patients with advanced Parkinson’s disease. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology, April 10–17 2010, Toronto, Canada
   Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
   PubMed Web of Science ®Google Scholar
• Sánchez-Castañeda C, Campdelacreu J, Miró J, et al. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson’s disease patients. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:250-1
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
   PubMed Web of Science ®Google Scholar
• Meppelink AM, Nyman R, van Laar T, et al. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease. Mov Disord 2010: published online 19 October 2010, doi: 10.1002/mds.23408
   Google Scholar
• Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 2008;23:1850-9
   PubMed Web of Science ®Google Scholar
• Potack JZ, Chokhavatia S. Complications of and controversies associated with percutaneous endoscopic gastrostomy. Report of a case and literature review. Medscape J Med 2008;10:142
   PubMedGoogle Scholar
• Schrag SF, Sharma R, Jaik NP, et al. Complications related to percutaneous endoscopic gastrostomy (PEG) tubes. A comprehensive clinical review. J Gastrointestin Liver Dis 2007;16:407-18
   PubMed Web of Science ®Google Scholar
• Löser C, Aschl G, Hébuterne X, et al. ESPEN guidelines on artificial enteral nutrition – percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005;24:848-61
   PubMed Web of Science ®Google Scholar
• Karlsborg M, Korbo L, Regeur L, et al. Duodopa pump treatment in patients with advanced Parkinson’s disease. Dan Med Bull 2010;57:A4155
   PubMedGoogle Scholar
• Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev 2006;CD005571
   Google Scholar
• Jafri NS, Mahid SS, Minor KS, et al. Meta-analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy. Aliment Pharmacol Ther 2007;25:647-56
   PubMed Web of Science ®Google Scholar
• Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2010: published online 11 October 2010, doi: 10.1001/archneurol.2010.260
   Google Scholar